本帖最后由 老马 于 2012-1-13 21:20 编辑
5 l# b k' r& f* C" Z; I
4 Z, ~# Q8 G- m! J6 K+ w爱必妥和阿瓦斯丁的比较
- h6 E) l' D! I* D/ h- I) ], N' t
* j! Q5 X) l) E, Ehttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" e3 z. V# q0 R# K4 Z& F
0 G6 c$ W* r! s% @9 q7 } ~& c; k
( {( K. Z" h: T/ Nhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/; O) d7 W: x$ f- J
==================================================
9 Z7 k8 ?! H. }- g/ J( R3 gOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
9 x1 Z2 I1 O2 k6 T+ uPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.- g; y' H& F' M/ t- |
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 V: ]1 A. s6 b% b+ G
|
显身卡
0 l& u, Z. N$ Q3 ^$ D8 r. p4 g3 W' r
